To evaluate effects of intravitreal ranibizumab and bevacizumab administration on ambulatory blood pressure monitoring (ABPM) recordings in normotensive patients with age-related macular degeneration ...
Genentech, Inc. would like to inform you of important safety information regarding off-label intravitreal use of AVASTIN® (bevacizumab). As of December 8, 2008, Genentech, Inc. through its global ...
Genentech is warning healthcare providers of 36 reports of intraocular adverse events following the off-label intravitreal use of Avastin (bevacizumab) injection. Twenty five of these events occurred ...
Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...
Please provide your email address to receive an email when new articles are posted on . Intravitreal bevacizumab may contribute to the need for longer ventilation support and a reduced chance of ...
Basel, Mai 1, 2012 - Recently announced results from two-year CATT[1] (Comparison of Age-related macular degeneration Treatment Trials) adds to the growing body of evidence, including CATT 1-year data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results